A

Advanced Medical Research Institute | Miami, FL

Research site

(Unclaimed)

Location

8780 SW 8 Street, Miami, Florida, United States of America

Site insights

Top conditions

Top treatments

Relamorelin

Vibegron

MT-2990

Triglycerides

Tolterodine

Aroxybutynin

AD109

ETX-018810

Atomoxetine

Pemafibrate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 21 total trials

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in particip...

Active, not recruiting

Hypertriglyceridemia

Cardiovascular Diseases

Drug: Placebo

Drug: Olezarsen

A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer

This Phase 3 study is a randomized, double-blind, vehicle-controlled, multiple-center, parallel study to evaluate efficacy and safety of ENERGI-F703...

Enrolling

Wound

Foot Ulcer

Drug: ENERGI-F703 GEL

Drug: ENERGI-F703 matched vehicle

Locations recently updated

Continuation Protocol for Obstructive Sleep Apnea (OSA)

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only

OSA

Drug: Aroxybutynin and Atomoxetine

Parallel-Arm Study to Compare AD109 to Placebo with Patients with OSA (SynAIRgy Study)

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Ob...

Active, not recruiting

OSA

Drug: Placebo

Drug: AD109